Home › Intelligence › Flash

MED-X Files S-1/A Amendment Ahead of NASDAQ IPO

Flash2026-10-16

MED-X, Inc. filed an amended Form S-1/A with the SEC on October 15, 2026, advancing its NASDAQ IPO. The medical device company develops orthopedic implants and digital surgical navigation systems. This amendment likely addresses SEC comments on financials, risk factors, or underwriting terms—signaling active engagement with the review process.

51CFO view：S-1/A amendments often trigger SEC comment letters requiring CFO-led responses within 48 hours—especially on revenue recognition, R&D capitalization, and ASC 718 assumptions. CFO must have proven experience managing SEC comment cycles and retrieving audit-trail evidence from ERP and sub-ledger systems.

MED-X, Inc. filed an amended Form S-1/A with the SEC on October 15, 2026, advancing its NASDAQ IPO. The medical device company develops orthopedic implants and digital surgical navigation systems. This amendment likely addresses SEC comments on financials, risk factors, or underwriting terms—signaling active engagement with the review process.

Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search

Where this touches your finance hire

Every listing event changes what you need from a CFO. Start from the step you are actually at.

What kind of CFO does a US IPO need? S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements. Read → Who owns SEC reporting and US GAAP? Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments. Read → What to do 18 months before filing Financial readiness: audit basis, internal control, equity restatement. Read →
‹ City Therapeutics Files S-1 Registration for NASDAQ IPO
DelphX Appoints New CFO with 15+ Years of Public-Company Finance Experience ›